Fig. 2

Features of Abs to OMGP in a highly reactive MS patient. a Reactivity of the serum (diluted 1:50) of patient 2492 in OMGP-TM CBA with a MFI ratio of 16.6. b Serum diluted 1:50 also recognized OMGP displayed with a GPI anchor. We calculated a ΔQ2 of 31.16%. c The Abs from this patient recognized OMGP also by ELISA. The serum (diluted 1: 100) was added to biotinylated OMGP bound to streptavidin (STV) plates and compared to STV plates alone. The bars represent the mean of 35 replicates with SD. d The longitudinal persistence of the anti-OMGP antibodies was analyzed with the OMGP-TM assay using serum samples from 12.6 to 15.6 years and plasma samples from 14, 14.5 and 17.7 years. Symbols represent at least means of two replicates, while first time point is measured 30x, second and last one 5x. Bars indicate SEM. Patient was treated with dimethyl fumarate during this period. e Isotype analysis of the OMGP-Abs in the OMGP-TM assay. The blue histogram displays IgG1 and IgG4 evaluation and grey the background of EGFP cells. f After OMGP autoantibody purification (Fig. S3), isotyping was reevaluated with the OMGP-GPI CBA. g C1q binding assay with patient’s derived purified OMGP autoantibodies using the STV-ELISA. Values represent mean of two experiments, bars indicate SEM. Two-way ANOVA with Bonferroni’s multiple comparison test is performed (p < 0.0001 ****, p < 0.01 **). h Identification of circulating OMGP-specific B cells. PBMC were differentiated to plasmablasts in 13 individual wells and then the anti-OMGP-reactivity was determined by OMGP-TM CBA